Biofrontera Inc.(BFRI)

Medical - Pharmaceuticals · Woburn, MA

$0.91+0.02 (+1.82%)

Delayed quote: Oct 6, 2026, 11:25 AM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T15:26:07.502Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:26:07.502Z.

Quote observation: 2026-10-06T15:25:20.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 11,613,914
Total debt · period ending 2026-06-30: 7,504,000
Cash · period ending 2026-06-30: 4,659,000
TTM operating EBITDA · period ending 2026-06-30: -3,685,000

FMP input reference: b47096c20191003074eea3dc75a1498d2bed5743fa2797f84e024bc92f81a74c

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BFRI EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

BFRI Competitors' EV/EBITDA Ratio

BFRI

Biofrontera Inc.

Current

Market Cap

$11.61M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PHIO

Phio Pharmaceuticals Corp.

vs BFRI

Market Cap

$11.73M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPRX

Kiora Pharmaceuticals, Inc.

vs BFRI

Market Cap

$11.30M

EV/EBITDA Ratio

N/A

TTM Avg

12.81x

3Y Avg

12.81x

5Y Avg

12.81x

BFRG

Bullfrog AI Holdings, Inc. Common Stock

vs BFRI

Market Cap

$11.94M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ADIL

Adial Pharmaceuticals, Inc.

vs BFRI

Market Cap

$11.28M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BIVI

BioVie Inc.

vs BFRI

Market Cap

$11.20M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLUR

Pluri Inc.

vs BFRI

Market Cap

$11.17M

EV/EBITDA Ratio

N/A

TTM Avg

1080.85x

3Y Avg

1080.85x

5Y Avg

1080.85x

IRIX

IRIDEX Corporation

vs BFRI

Market Cap

$12.12M

EV/EBITDA Ratio

N/A

TTM Avg

133.45x

3Y Avg

63.52x

5Y Avg

51.85x

GDTC

CytoMed Therapeutics Limited

vs BFRI

Market Cap

$10.94M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LSTA

Lisata Therapeutics, Inc.

vs BFRI

Market Cap

$10.93M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Biofrontera Inc. (BFRI)	$11.61M	N/A	N/A	N/A	N/A
Phio Pharmaceuticals Corp. (PHIO)vs ›	$11.73M	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals, Inc. (KPRX)vs ›	$11.30M	N/A	12.81x	12.81x	12.81x
Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›	$11.94M	N/A	N/A	N/A	N/A
Adial Pharmaceuticals, Inc. (ADIL)vs ›	$11.28M	N/A	N/A	N/A	N/A
BioVie Inc. (BIVI)vs ›	$11.20M	N/A	N/A	N/A	N/A
Pluri Inc. (PLUR)vs ›	$11.17M	N/A	1080.85x	1080.85x	1080.85x
IRIDEX Corporation (IRIX)vs ›	$12.12M	N/A	133.45x	63.52x	51.85x
CytoMed Therapeutics Limited (GDTC)vs ›	$10.94M	N/A	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$10.93M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics